NDAINJECTIONINJECTABLE
Approved
Oct 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% (dopamine hydrochloride) by B. Braun is clinical pharmacology dopamine is a natural catecholamine formed by the decarboxylation of 3,4-dihydroxyphenylalanine (dopa). Approved for hemodynamic status in patients in shock. First approved in 1986.
Drug data last refreshed 12h ago · AI intelligence enriched 18h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Dopamine hydrochloride in dextrose 5% is an intravenous catecholamine agonist indicated for management of hemodynamic status in patients in shock. It works through dose-dependent activation of dopamine, beta-1, and alpha-1 adrenergic receptors, producing vasodilation at low doses and positive chronotropic/inotropic effects at intermediate doses.
LOE Approaching
This product is approaching end-of-life, signaling contract consolidation and reduced promotional investment opportunities.
Mechanism of Action
CLINICAL PHARMACOLOGY Dopamine is a natural catecholamine formed by the decarboxylation of 3,4-dihydroxyphenylalanine (DOPA). It is a precursor to norepinephrine in noradrenergic nerves and is also a neurotransmitter in certain areas of the central nervous system, especially in the nigrostriatal…
Worked on DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% at B. Braun? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.